Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND ‐9-Reference-Cited by-同舟云学术

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND ‐9

Published:2018-07-25 Issue:9 Volume:109 Page:2863-2872
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Hida Toyoaki¹^ORCID,Seto Takashi²,Horinouchi Hidehito³,Maemondo Makoto⁴,Takeda Masayuki⁵,Hotta Katsuyuki⁶,Hirai Fumihiko²,Kim Young Hak⁷,Matsumoto Shingo⁸,Ito Masayuki⁹,Ayukawa Koichi⁹,Tokushige Kota⁹,Yonemura Masataka⁹,Mitsudomi Testuya⁵,Nishio Makoto¹⁰

Affiliation:

1. Aichi Cancer Center Hospital Aichi Japan

2. National Kyushu Cancer Center Fukuoka Japan

3. National Cancer Center Hospital Tokyo Japan

4. Miyagi Cancer Center Miyagi Japan

5. Kindai University Osaka Japan

6. Okayama University Hospital Okayama Japan

7. Kyoto University Hospital Kyoto Japan

8. National Cancer Center Hospital East Kashiwa Japan

9. Novartis Pharma K.K. Tokyo Japan

10. The Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo Japan

Funder

Novartis Pharma

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.13721

Reference30 articles.

1. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

2. Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

3. US Food and Drug Administration.Crizotinib US prescribing information.2014.http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202570s011lbl.pdf. Accessed May 23 2018.

4. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

5. Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer;Lung Cancer;2024-08

2. Analysis of the resistance profile of real-world alectinib first-line therapy in patients with ALK rearrangement-positive advanced non-small cell lung cancer using organoid technology in one case of lung cancer;Journal of Thoracic Disease;2024-06

3. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study;Cancer Communications;2024-02-29

4. Alectinib continuation beyond progression in ALK-positive non-small cell lung cancer with alectinib-refractory;Translational Lung Cancer Research;2024-01

5. Diagnosis and treatment of anaplastic lymphoma kinase (ALK) rearranged non−small cell lung cancer;Lung Cancer;2024